

Hemant Bhutani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212096/publications.pdf>

Version: 2024-02-01

18
papers

626
citations

1163117

8
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

621
citing authors

#	ARTICLE	IF	CITATIONS
1	A methodology employing retention modeling for achieving control space in liquid chromatography method development using quality by design approach. Journal of Chromatography A, 2021, 1635, 461658.	3.7	5
2	U.S. FDA Approved Drugs from 2015 to June 2020: A Perspective. Journal of Medicinal Chemistry, 2021, 64, 2339-2381.	6.4	314
3	Development of HPLC-CAD stability indicating assay method for polyethylene glycol-conjugated phospholipid (DMPE-PEG 2000) and identification of its degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2021, 198, 113967.	2.8	3
4	A Tribute to Professor Saranjit Singh - A Critical Thinker, Innovator, Mentor, and Educator. Journal of Pharmaceutical Sciences, 2021, , .	3.3	0
5	Identification of extractables by liquid chromatography-high resolution mass spectrometry: A case study to understand the extraction profile of different disposable syringes. Journal of Pharmaceutical and Biomedical Analysis, 2020, 191, 113602.	2.8	6
6	Quantification of solid-state impurity with powder X-ray diffraction using laboratory source. Powder Diffraction, 2020, 35, 226-232.	0.2	6
7	Rapid and efficient chiral method development for lamivudine and tenofovir disoproxil fumarate fixed dose combination using ultra-high performance supercritical fluid chromatography: A design of experiment approach. Journal of Chromatography A, 2020, 1625, 461257.	3.7	16
8	Cross-linking of poly (vinyl alcohol) films under acidic and thermal stress. European Journal of Pharmaceutical Sciences, 2020, 152, 105429.	4.0	7
9	Solid State Behavior of Impurities during In-Process Phase Purity Analysis of an API. Organic Process Research and Development, 2019, 23, 269-273.	2.7	2
10	Supramolecular Chemistry of BrettPhos and BrettPhos Oxide: Breakup of Isostructurality via Order to Disorder Phase Transitions. Crystal Growth and Design, 2017, 17, 1982-1990.	3.0	7
11	Screening of bulk drug samples and anti-tuberculosis products for the presence of therapeutically less active diastereomeric (R,S) form of ethambutol dihydrochloride. Indian Journal of Tuberculosis, 2008, 55, 192-8.	0.7	2
12	ICH guidance in practice: Validated stability-indicating HPLC method for simultaneous determination of ampicillin and cloxacillin in combination drug products. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 769-773.	2.8	43
13	LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1213-1220.	2.8	97
14	Study of the interaction between rifapentine and isoniazid under acid conditions. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 1438-1441.	2.8	19
15	Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. Journal of Pharmaceutical and Biomedical Analysis, 2005, 39, 892-899.	2.8	50
16	Behavior of Moisture Gain and Equilibrium Moisture Contents (EMC) of Various Drug Substances and Correlation with Compendial Information on Hygroscopicity and Loss on Drying. Pharmaceutical Development and Technology, 2005, 10, 489-497.	2.4	22
17	Drug-Drug Interaction Studies on First-Line Anti-tuberculosis Drugs. Pharmaceutical Development and Technology, 2005, 10, 517-524.	2.4	27
18	Low-Level Quantification of tert-Butyl Nitrite in a Pharmaceutical Intermediate. Organic Process Research and Development, 0, , .	2.7	0